Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
9.860
-0.090 (-0.90%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about 89Bio Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
December 07, 2023
Via
Benzinga
Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
December 07, 2023
U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
December 04, 2023
89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in
Via
Benzinga
Exposures
Product Safety
Analyst Ratings for 89bio
November 28, 2023
Via
Benzinga
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
November 27, 2023
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with
Via
Benzinga
Analyst Expectations for 89bio's Future
October 11, 2023
Via
Benzinga
The Latest Analyst Ratings for 89bio
September 22, 2023
Via
Benzinga
Analyst Ratings for 89bio
August 10, 2023
Via
Benzinga
BTIG Maintains Buy Rating for 89bio: Here's What You Need To Know
July 03, 2023
Via
Benzinga
Why Shares of 89bio Plummeted on Tuesday
October 10, 2023
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Via
The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
October 10, 2023
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 10, 2023
Via
Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 10, 2023
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
Via
Benzinga
What 6 Analyst Ratings Have To Say About 89bio
July 03, 2023
Via
Benzinga
Analyst Ratings for 89bio
May 08, 2023
Via
Benzinga
Why Akero Therapeutics Stock Is Crashing Today
October 10, 2023
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
Via
The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
October 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Gain; PepsiCo Posts Upbeat Earnings
October 10, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
October 10, 2023
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 10, 2023
Via
Benzinga
3 Biotech Buyout Targets to Watch
April 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Via
The Motley Fool
Over $40M Bet On 89bio? Check Out These 3 Stocks Insiders Are Buying
March 31, 2023
Although US stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
July 03, 2023
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to...
Via
Benzinga
Why Shares of 89bio Soared This Week
March 24, 2023
The company released positive results for its lead therapy.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
June 13, 2023
Via
Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
March 23, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 23, 2023
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
Via
Benzinga
89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday
March 23, 2023
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.